Bristol-Myers's Celgene Deal Is Record for Pharma
(Bloomberg) -- Bristol-Myers Squibb Co.’s acquisition of Celgene Corp. values the target at $88.8 billion, including net debt, according to data compiled by Bloomberg. That surpasses Pfizer Inc.’s purchase of Warner-Lambert, announced in 1999, as the biggest-ever acquisition of a pharmaceutical or biotech company, the data show. Pfizer’s failed bid for AstraZeneca in 2014 would have taken the top spot had it gone through.
©2019 Bloomberg L.P.